Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL4RPep-1-KLA
- Development stage
- Unknown
- Lead developer
- Kyungpook National University
- Modality
- Peptides
01
Overview
IL4RPep-1-KLA: sourced facts only. name: "To target IL4R-high tumor cells, we exploited IL4RPep-1-KLA composed of IL4RPep-1, an IL4R-binding peptide, and (KLAKLAK)2, a cytotoxic peptide." [DOI:10.1158/1538-7445.am2022-3422]; target: "To target IL4R-high tumor cells, we exploited IL4RPep-1-KLA composed of IL4RPep-1, an IL4R-binding peptide, and (KLAKLAK)2, a cytotoxic peptide." [DOI:10.1158/1538-7445.am2022-3422]; developer: "1School of Medicine, Kyungpook National University, Daegu, Republic of Korea." [DOI:10.1158/1538-7445.am2022-3422]; modality: "To target IL4R-high tumor cells, we exploited IL4RPep-1-KLA composed of IL4RPep-1, an IL4R-binding peptide, and (KLAKLAK)2, a cytotoxic peptide." [DOI:10.1158/1538-7445.am2022-3422]
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on IL4RPep-1-KLA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL4RPep-1-KLA.